FDA grants accelerated approval to zanidatamab-hrii

2 days ago · On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.) for biliary tract cancer.

CouponFollow Extension

52%
OFF

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For …

6 days from now

1 day ago · FDA grants accelerated approval to Jazz Pharma's Ziihera for HER2-positive biliary tract cancer with a 52% ORR and 14.9-month median DOR. Zymeworks earns $25 million …

benzinga.com

$25
OFF

Zymeworks Hold Rating: Balancing FDA Milestones With Market …

6 days from now

1 day ago · The accelerated FDA approval of zanidatamab for HER2-positive biliary tract cancer is a significant milestone, triggering a substantial $25 million payment to Zymeworks.

businessinsider.com

52%
OFF

Jazz Pharma's Ziihera Wins FDA Approval With 52% Response Rate …

6 days from now

2 days ago · Jazz Pharmaceuticals announced FDA accelerated approval of Ziihera (zanidatamab-hrii) for treating adults with previously treated, unresectable or metastatic HER2 …

stocktitan.net

FAQs about FDA grants accelerated approval to zanidatamab-hrii Coupon?

Does Jazz Pharmaceuticals offer zanidatamab for biliary tract cancer?

Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will be marketed under the trade name Ziihera. ...

Can ziihera be used for metastatic biliary tract cancer?

The drug, sold under the brand name Ziihera, is approved for use in previously treated adults with metastatic HER2-positive biliary tract cancer. HER2 is a protein that stimulates quick growth of cancer cells. Its presence in solid tumor form includes biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers. ...

What is ziihera (zanidatamab-hrii)?

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced the U.S. Food and Drug Administration accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. ...

What is Jazz Pharmaceuticals' zanidatamab-hrii?

Nov 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' (JAZZ.O) drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday. The drug, sold under the brand name Ziihera, is approved for use in previously treated adults with metastatic HER2-positive biliary tract cancer. ...

Does Jazz Pharmaceuticals plc hold ziihera?

Jazz acquired exclusive rights to develop and market across Ziihera in all territories except Asia/Pacific (where the drug has been licensed to BeiGene) from Zymeworks in 2022. JAZZ currently carries a Zacks Rank #3 (Hold). Jazz Pharmaceuticals PLC price | Jazz Pharmaceuticals PLC Quote ...

Why did ziihera receive accelerated approval?

Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial. ...